Generics Bulletin Editor’s Picks For Q1 2022

Highlights Across The Off-Patent Sector From January To March 2022

 
• By Dave Wallace
  
Q1 First Quarter Post It Note
The first quarter of 2022 brought biosimilars deals, warnings over generic pricing pressure, and strategic updates from the J.P Morgan conference • Source: Constantin Stanciu / Alamy Stock Photo

More from Biosimilars

More from Products